Editorials
All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies .......................... 1223
K.P. Liao, V. Bykerk
Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis J.E. Homik ................................. 1225
Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri .......................... 1228
Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? C.S. Lau ...................................................... 1231

Review
Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists E.C. Keystone, K.A. Papp, W. Wobeser .......................... 1234

Articles
A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis A. Svärd, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh .......................................................... 1265
Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry J.A. Markenson, A. Gibofsky, W.R. Palmer, et al .......................... 1273
Time to Treatment for New Patients with RA in a Major Metropolitan City S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier .................................................. 1282
Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China X. Feng, Y. Zou, W. Pan, et al .................................................. 1289

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression A. Mak, Y. Liu, R.C-M Ho .......................................................... 1296
Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos .............................................. 1304
Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms A.D. Askashe, I. Castrejón, T. Pincus .................................................. 1309
Late-age Onset SSc R.L. Manno, F.M. Wiegley, A.C. Gelber, L.K. Hummers .............................................. 1317
Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group .................................................. 1326
Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy, A Randomized Controlled Trial S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi .................................................. 1335
Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation S.J. Pedersen, P. Chiowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych .............................................. 1349
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene S. Borghini, M. Fiore, M. Di Duca, et al .............................................. 1378

Free online via JRheum Full Release option
Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldfarb 1415
P.A. MacDonald, B. Hunt, L. Gunawardhana 1415
Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study
Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
A.A. Khan, L.P. Rios, G.K.B. Sandor, et al 1396
Longterm Therapeutic Response to Milnacipran Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group 1403
Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Consequence Analysis and RCT
Pedicriatic Rheumatology
Heterotopic Ossification of the TMJ in JIA
S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace 1423
MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang 1429
Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry
B. Bader-Meunier, H. Decaluwe, C. Bernardes, et al, for the Club Rhumatismes et Inflammation 1436
Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al 1442
OMERACT 10
10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010
Introduction 1448
Disease-specific Outcomes
ToPhus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al 1458
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
L.K. Stamp, P.P. Khanna, N. Dalbeth, et al 1462
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
P.A. Merkel, S.Z. Aydin, M. Boers, et al 1480
Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group 1487
Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG
L.C. Coates, A. Muntaz, P.S. Helliswell, et al 1496
Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde 1502
Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group 1514
Correspondence
Where in the World is Oral Triamcinolone? L. Roger 1519
Reply R. Alten 1519
Lupus Related Longitudinal Myelitis D.M. Wingerchuk, B.G. Wemshenker 1520
Reply P. Zotos 1521
Who Discovered the ESR? A. Grzybowski, J.J. Sak 1521
Reply E.L. Matteson, C.S. Crowson 1523
Letters
Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brasington 1525
AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Ferreira, C. Jorgensen 1527
Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis M. Uh, I.A. McCormick, J.T. Kelsall 1528
Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan 1529
Corrections
Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbaloochi 1534
Meetings in Rheumatology